The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Abstract
BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer. METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival. RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P<0.001). CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach
McCulloch, P. G., Nita, M. E., Kazi, H. A., & Gama-Rodrigues, J. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001964.pub3 · Cited by 134
RetractedMacdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Extended Lymph-Node Dissection for Gastric Cancer
Bonenkamp, J. J., Hermans, J., Sasako, M., Welvaart, K., Songun, I., Meyer, S., Plukker, J. T. M., Van Elk, P., Obertop, H., Gouma, D. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401202 · Cited by 1,583
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459
for the Surgical Co-operative Group, Cuschieri, A., Weeden, S., Fielding, J., Bancewicz, J., Craven, J., Joypaul, V, Sydes, M., & Fayers, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690243 · Cited by 1,373
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Hartgrink, H. H., van de Velde, C. J. H., Putter, H., Bonenkamp, J. J., Klein Kranenbarg, E., Songun, I., Welvaart, K., van Krieken, J. H. J. M., Meijer, S., Plukker, J. T. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.026 · Cited by 918
Self-citationWebb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Self-citationRoss, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Self-citationPrognostic relevance of systematic lymph node dissection in gastric carcinoma
German Gastric Carcinoma Study Group, Siewert, J. R., Böttcher, K., Roder, J. D., Busch, R., Hermanek, P., & Meyer, H. J. (1993) · Journal of British Surgery · doi:10.1002/bjs.1800800829 · Cited by 452
Cited by
Items 101–126 of 126
Nilsson, P. J., van Etten, B., Hospers, G. A., Påhlman, L., van de Velde, C. J., Beets-Tan, R. G., Blomqvist, L., Beukema, J. C., Kapiteijn, E., Marijnen, C. A., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-279 · Cited by 293
Self-citationCunningham, D., Stenning, S. P., Smyth, E. C., Okines, A. F., Allum, W. H., Rowley, S., Stevenson, L., Grabsch, H. I., Alderson, D., Crosby, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30043-8 · Cited by 289
Self-citationKorean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., Gockel, I., Gerdes, B., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409408 · Cited by 286
Stahl, M., Walz, M. K., Riera-Knorrenschild, J., Stuschke, M., Sandermann, A., Bitzer, M., Wilke, H., & Budach, W. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.027 · Cited by 283
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Elliott, J. A., Doyle, S. L., Murphy, C. F., King, S., Guinan, E. M., Beddy, P., Ravi, N., & Reynolds, J. V. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002398 · Cited by 281
Surgical Management of Gastric Cancer: A Review
Li, G. Z., Doherty, G. M., & Wang, J. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.0182 · Cited by 278
Tan, B. H. L., Brammer, K., Randhawa, N., Welch, N. T., Parsons, S. L., James, E. J., & Catton, J. A. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.11.040 · Cited by 277
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
Self-citationOutcomes After Transhiatal and Transthoracic Esophagectomy for Cancer
Chang, A. C., Ji, H., Birkmeyer, N. J., Orringer, M. B., & Birkmeyer, J. D. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.10.007 · Cited by 275
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer
Zhai, J., Shen, J., Xie, G., Wu, J., He, M., Gao, L., Zhang, Y., Yao, X., & Shen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.002 · Cited by 272
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269
Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer
Awad, S., Tan, B. H., Cui, H., Bhalla, A., Fearon, K. C. H., Parsons, S. L., Catton, J. A., & Lobo, D. N. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2011.08.008 · Cited by 269
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Buckley, A. M., Lynam-Lennon, N., O’Neill, H., & O’Sullivan, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0247-2 · Cited by 254
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35431-x · Cited by 253
Cheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30108-6 · Cited by 219
Oba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt270 · Cited by 168
Muti, H. S., Heij, L. R., Keller, G., Kohlruss, M., Langer, R., Dislich, B., Cheong, J.-H., Kim, Y.-W., Kim, H., Kook, M.-C., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00133-3 · Cited by 126
Self-citationLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0765-8 · Cited by 71
Matsuyama, J., Doki, Y., Yasuda, T., Miyata, H., Fujiwara, Y., Takiguchi, S., Yamasaki, M., Makari, Y., Matsuura, N., Mano, M., et al. (2007) · Surgery · doi:10.1016/j.surg.2006.11.007 · Cited by 64
Chen, M., Lu, J., Wei, W., Lv, Y., Zhang, X., Yao, Y., Wang, L., Ling, T., & Zou, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161198 · Cited by 61
Jiang, Y., Liang, X., Han, Z., Wang, W., Xi, S., Li, T., Chen, C., Yuan, Q., Li, N., Yu, J., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00065-0 · Cited by 58
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer
Lin, X.-M., Li, S., Zhou, C., Li, R.-Z., Wang, H., Luo, W., Huang, Y.-S., Chen, L.-K., Cai, J.-L., Wang, T.-X., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105610 · Cited by 43
Wang, D., Li, W., Yin, L., Du, Y., Zhang, S., & Suo, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11350 · Cited by 12
Metadata
- Authors
- Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., & Chua, Y. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-06
- Volume
- 355
- Issue
- 1
- Pages
- 11-20
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115072149
- Cited by
- 6,334
- References
- 20
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.